Lead Product(s): BP-101
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: BP-101
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
The double-blind placebo-controlled study is expected to enrol 476 patients across 13 sites. BP-101 is a synthetic peptide administered through a nasal spray and has been supplied for this study by well established peptide manufacturers in Switzerland and the UK.